Boston Scientific received European regulatory approval for its bare metal REBEL Platinum Chromium Coronary Stent System for treatment of coronary artery disease. The stent is essentially the Promus PREMIER but without the everolimus drug coating.
The stent is available with diameters from 2.25 mm to 4.50 mm and lengths of 8 mm to 32 mm. In the U.S. the REBEL remains an investigational device and is not available for sale.
From the announcement:
“I am glad to have a bare metal stent that performs like the PREMIER DES but allows me to treat patients who are not candidates for DES therapy,” said Prof. Didier Carrie, M.D., Ph.D., an investigator for the OMEGA clinical trial at Centre Hopital Universitaire, Rangueil, France. “In addition to its great visibility and deliverability, the platinum chromium stent architecture features low recoil that is particularly important for patients treated with bare metal stents.”
The REBEL Stent System features unparalleled visibility, low recoil, exceptional radial strength and fracture resistance, while improving axial strength and deliverability. Its enhanced low-profile delivery system also features a shorter, more visible tip, a dual-layer balloon and a Bi-Segment™ inner lumen catheter designed to facilitate precise stent delivery across challenging lesions.
Flashback: Boston Sci Promus PREMIER Drug Eluting Stent Now Available in Europe…; Boston Scientific Awarded FDA Approval for Promus Premier Stent…
Press release: Boston Scientific Receives CE Mark Approval for REBEL™ Platinum Chromium Coronary Stent System…
